Industry & Policy News

[University of Toronto] HDAX Therapeutics is focused on developing treatments for peripheral nerve damage, which can result from chemotherapy or radiation.

[FDA] The US FDA cleared for marketing the first over-the-counter continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is an integrated CGM intended for anyone 18 years and older who does not use insulin.

[Johnson & Johnson] Johnson & Johnson announced the submission of a supplemental Biologics License Application to the US FDA seeking approval of TREMFYA® for treatment of adults with moderately to severely active ulcerative colitis.

[University of Strathclyde] Researchers at the University of Strathclyde have been awarded £2.6 million to develop a preclinical lead drug candidate targeted at advanced prostate and colorectal cancers.

[Monte Rosa Therapeutics, Inc.] Monte Rosa Therapeutics, Inc. announced a novel development candidate, MRT-8102. MRT-8102 is expected to be developed for the treatment of inflammatory diseases driven by interleukin-1β and the NLRP3 inflammasome, which are critical elements of the inflammatory process.

[Sifted] Cellcolabs has raised $8.7m from angel investors to expand production facilities and grow employee headcount. The Sweden-based company manufactures specialised stem cells that can be used to develop cell therapy treatments for diseases associated with inflammation.